Clinical pathways for pancreatic neuroendocrine tumors.

about

Update on pancreatic neuroendocrine tumors.Pancreatic Neuroendocrine Tumors: an Update.Advancements in pancreatic neuroendocrine tumors.

P2860

Q34453043-4E458014-DC58-4338-A42C-00D16CB5E480 Q36400062-C4A2350D-A8B4-4839-B843-C2E48CD72824 Q38125257-5BEFAC83-3839-4F1C-98B0-F15C78A2D146

P2860

Clinical pathways for pancreatic neuroendocrine tumors.

Item

http://www.wikidata.org/entity/Q38015767

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Clinical pathways for pancreatic neuroendocrine tumors.

@en

type

Item

label

Clinical pathways for pancreatic neuroendocrine tumors.

@en

prefLabel

Clinical pathways for pancreatic neuroendocrine tumors.

@en

P1476

Clinical pathways for pancreatic neuroendocrine tumors.

@en

P2093

Angela Alistar

http://www.w3.org/2001/XMLSchema#string

Max Sung

http://www.w3.org/2001/XMLSchema#string

Michelle Kim

http://www.w3.org/2001/XMLSchema#string

Randall F Holcombe

http://www.w3.org/2001/XMLSchema#string

P2860

Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies

Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience.

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.

Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Everolimus for advanced pancreatic neuroendocrine tumors.

Hereditary pancreatic endocrine tumours.

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.

P2888

s12029-012-9397-y

P304

532-540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12029-012-9397-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22661335

http://www.w3.org/2001/XMLSchema#string

Clinical pathways for pancreatic neuroendocrine tumors.

about

P2860

P2860

Clinical pathways for pancreatic neuroendocrine tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698